So-Young Reports Unaudited First Quarter 2026 Financial Results

Strong revenue growth, but losses are widening and profitability remains elusive.

What the company is saying

So-Young International Inc. positions itself as the leading aesthetic treatment platform in China, emphasizing rapid expansion and operational scale as the core of its growth story. The company highlights a 45.6% year-over-year revenue increase to RMB432.8 million and a 185.8% surge in aesthetic treatment services revenues, framing these as evidence of successful business expansion. Management claims that the number of verified treatment visits and treatments performed more than doubled, and that user engagement is robust, with active users exceeding 213,000 and core members growing by over 11,700 in the quarter. The announcement stresses that 41 out of 54 branded aesthetic centers achieved profitability and 48 generated positive operating cash flow, suggesting operational efficiency and scalability. Forward-looking statements project continued strong growth, with Q2 2026 aesthetic treatment services revenues expected to rise by over 112% year-over-year. However, the company buries the fact that net losses have increased, and omits any discussion of when or how it expects to achieve overall profitability. The tone is upbeat and confident, using language like "exceeded the high end of guidance" and "confident that these ongoing efforts will create lasting value," but avoids specifics on cost control or margin improvement. Mr. Xing Jin, Co-Founder and CEO, is the only notable individual identified, and his involvement signals continuity and founder-led execution, but does not introduce new external validation. This narrative fits a classic high-growth, high-burn investor relations strategy, focusing on top-line momentum and operational milestones while downplaying persistent losses. Compared to prior communications (where history is unavailable), the messaging here is consistent with a company in aggressive expansion mode, with no evidence of a pivot toward profitability.

What the data suggests

The disclosed numbers show that So-Young’s total revenues for Q1 2026 were RMB432.8 million, up from RMB297.3 million in Q1 2025—a 45.6% increase. Aesthetic treatment services revenues grew even faster, from RMB98.8 million to RMB282.4 million, a 185.8% jump, indicating that the company’s core business is scaling rapidly. However, net loss attributable to the company widened from RMB33.1 million to RMB49.2 million, and non-GAAP net loss also increased from RMB31.5 million to RMB46.6 million, showing that higher revenues have not translated into improved bottom-line performance. Operationally, the number of verified treatment visits rose from 54,400 to 148,000, and treatments performed increased from 123,400 to over 325,800, both more than doubling year-over-year. The company reports that 41 of its 54 centers were profitable and 48 generated positive operating cash flow, but the aggregate business remains loss-making, suggesting that scale alone is not yet sufficient to offset corporate overhead and expansion costs. Cost of revenues rose 65.8% to RMB251.0 million, and total operating expenses increased 26.6% to RMB239.7 million, with sales and marketing expenses up 33.7% and G&A up 42.5%. The company’s cash position declined from RMB936.4 million at year-end 2025 to RMB880.0 million at March 31, 2026, reflecting ongoing cash burn. Some claims, such as exceeding guidance or sequential core member growth, cannot be independently verified due to missing baseline data. An independent analyst would conclude that while the company is delivering on growth, it is not yet demonstrating operating leverage or a clear path to profitability, and the risk of continued losses remains high.

Analysis

The announcement is largely factual, with the majority of claims supported by concrete, realised financial and operational data for the reported quarter. The only significant forward-looking statement is the revenue guidance for the next quarter, which is a standard and expected disclosure in earnings releases. There is no evidence of narrative inflation or exaggerated language; the tone is positive but proportionate to the strong revenue and user growth metrics. While net losses have increased, this is transparently disclosed and not downplayed. There are no large, aspirational claims about future projects, capital outlays, or long-term benefits that lack supporting evidence. The gap between narrative and evidence is minimal, and the data supports the positive framing.

Risk flags

• ●Operational risk: The company is aggressively expanding its branded aesthetic centers, with 54 operational as of March 31, 2026. Rapid expansion can strain management bandwidth, dilute operational focus, and increase the risk of execution missteps, especially as only 41 centers are profitable and 48 generate positive cash flow, leaving a material minority underperforming.
• ●Financial risk: Despite strong revenue growth, net losses have widened from RMB33.1 million to RMB49.2 million year-over-year. This indicates that the business model is not yet self-sustaining, and continued losses could pressure the company’s cash reserves and necessitate future capital raises.
• ●Disclosure risk: Some key claims—such as exceeding the high end of guidance and sequential core member growth—cannot be independently verified from the disclosed data, as prior guidance and baseline figures are omitted. This limits transparency and makes it harder for investors to assess the credibility of management’s narrative.
• ●Pattern-based risk: The company’s communications focus heavily on top-line growth and operational milestones, while consistently downplaying or omitting discussion of profitability, margin trends, or cost control. This pattern suggests a bias toward growth-at-all-costs, which can be unsustainable if not eventually matched by operating leverage.
• ●Timeline/execution risk: While near-term revenue guidance is provided, there is no stated timeline or plan for achieving profitability. Investors face the risk that losses will persist or worsen, especially if revenue growth slows or cost discipline is not improved.
• ●Capital intensity risk: The business model requires significant ongoing investment in new centers, branding, and user acquisition, as evidenced by rising sales, marketing, and G&A expenses. High capital intensity increases the risk that the company will need to raise additional funds, potentially diluting existing shareholders.
• ●Geographic concentration risk: All operational centers are located in China, exposing the company to country-specific regulatory, economic, and competitive risks. Any adverse changes in the Chinese healthcare or consumer environment could disproportionately impact results.
• ●Leadership concentration risk: The company is led by its co-founder and CEO, Mr. Xing Jin. While founder leadership can drive vision and execution, it also concentrates decision-making and may limit external oversight or challenge to the current strategy.

Bottom line

For investors, this announcement confirms that So-Young International Inc. is delivering exceptional revenue and user growth, but at the cost of widening losses and ongoing cash burn. The company’s narrative of operational scale and center-level profitability is credible at the unit level, but does not translate into overall profitability for the business as a whole. The absence of a clear path or timeline to break-even is a significant gap, and management’s omission of margin or cost control discussion is a red flag for those seeking sustainable returns. The involvement of Mr. Xing Jin as CEO signals continuity and founder commitment, but does not provide new external validation or reduce execution risk. To change this assessment, the company would need to demonstrate narrowing net losses, provide verifiable evidence for all qualitative claims, and articulate a credible plan for achieving profitability. Key metrics to watch in the next reporting period include net loss trajectory, cash burn rate, center-level profitability trends, and whether revenue growth continues at the forecasted pace. Investors should treat this as a signal to monitor rather than act on immediately: the growth is real, but the lack of operating leverage and persistent losses mean the risk/reward is not yet compelling. The single most important takeaway is that So-Young is a high-growth, high-burn story—until it proves it can convert scale into profits, caution is warranted.

Announcement summary

So-Young International Inc. (NASDAQ:SY), the leading aesthetic treatment platform in China, announced its unaudited financial results for the first quarter ended March 31, 2026. Total revenues were RMB432.8 million (US$62.7 million), up 45.6% from RMB297.3 million in the same period of 2025, primarily due to business expansion of branded aesthetic centers. Aesthetic treatment services revenues reached RMB282.4 million (US$40.9 million), an increase of 185.8% year-over-year, exceeding the high end of guidance. Net loss attributable to So-Young International Inc. was RMB49.2 million (US$7.1 million), compared with RMB33.1 million in the same period of 2025. The number of verified treatment visits to branded aesthetic centers was approximately 148,000, and the number of verified aesthetic treatments performed surpassed 325,800. As of March 31, 2026, So-Young had 54 fully operational branded aesthetic centers across sixteen major cities in China, with 41 centers achieving profitability and 48 generating positive quarterly operating cash flow. For the second quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB307.0 million (US$44.5 million) and RMB317.0 million (US$46.0 million), representing an 112.6% to 119.5% increase from the same period in 2025.

Disagree with this article?